Registration - Amendment
W STRATEGIES, LLC for HORIZON PHARMA USA, INC.
Firm
Client
Income
—
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to orphan drugs and the value of innovative medicines. March 2016 CMS proposed rule implementing a new Part B drug payment model. H.R. 5122 - To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX New | Asst. for Policy, Speaker Dennis Hastert; Admin. Asst., Legislative Director, Legislative Asst., Cong. Porter Goss; House Rules Comm. Assoc., Subcommittee Staff Director. |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| HORIZON PHARMA PLC | United Kingdom | United Kingdom | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.